Oral vancomycin shows promise in treating pouchitis in patients with primary sclerosing cholangitis and ulcerative colitis. In this study, vancomycin helped reduce stool frequency, urgency, and incontinence. More research is needed to confirm its long-term benefits and best treatment practices.
Dunleavy, K., Meyers, A.C., Violante, T., Kassmeyer, B., Urquhart, S.A., Coelho-Prabhu, N., et al. (2025). Oral Vancomycin as an Emerging Therapy for Inflammatory Pouch Conditions Associated with Primary Sclerosing Cholangitis. INFLAMMATORY BOWEL DISEASES, 31(9), 2597-2601 [10.1093/ibd/izaf117].
Oral Vancomycin as an Emerging Therapy for Inflammatory Pouch Conditions Associated with Primary Sclerosing Cholangitis
Violante T.Writing – Review & Editing
;
2025
Abstract
Oral vancomycin shows promise in treating pouchitis in patients with primary sclerosing cholangitis and ulcerative colitis. In this study, vancomycin helped reduce stool frequency, urgency, and incontinence. More research is needed to confirm its long-term benefits and best treatment practices.File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
